Table 3.

Unadjusted and Adjusted HRs Associated With ADT Plus RT Relative to ADT Alone

Observational Study Estimate	RCT Cohort				Elderly Cohort				Screen-Detected Cohort
	Cause-Specific Mortality		All-Cause Mortality		Cause-Specific Mortality		All-Cause Mortality		Cause-Specific Mortality		All-Cause Mortality
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
Unadjusted*	0.39	0.34 to 0.45	0.57	0.54 to 0.61	0.42	0.37 to 0.49	0.53	0.50 to 0.56	0.20	0.16 to 0.26	0.41	0.37 to 0.46
Propensity score	0.43	0.37 to 0.49	0.63	0.59 to 0.67	0.51	0.44 to 0.59	0.63	0.59 to 0.67	0.25	0.19 to 0.33	0.50	0.45 to 0.55
Instrumental variable	—	—	0.65	0.45 to 0.96	—	—	0.66	0.54 to 0.81	—	—	0.42	0.28 to 0.64
Randomized trial estimates
NCIC CTG (Warde et al,4 2011)	0.54	0.27 to 0.78	0.77	0.61 to 0.98
SPCG-7 (Widmark et al,3 2009)	0.44	0.30 to 0.66	0.68	0.52 to 0.89

Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; RCT, randomized clinical trial; RT, radiotherapy; SPCG-7, Scandinavian Prostate Cancer Group Study 7.

^*Univariable comparison between ADT and ADT plus RT.